Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I/II study.
Zhenyu Pan, Guozi Yang, Hua He...
https://pubmed.ncbi.nlm.nih.gov/32733606/Actively Recruiting
Led by Guangzhou Medical University · Updated on 2025-09-29
34
Participants Needed
1
Research Sites
21 weeks
Total Duration
Leptomeningeal metastases LM is a serious and often fatal complication in patients with HER2-negative breast cancer, involving cancer cells spreading within the space around the brain and spinal cord. This clinical trial aims to evaluate the safety, feasibility, and potential benefits of combining Sacituzumab Govitecan with intrathecal pemetrexed chemotherapy as a new treatment approach for LM from HER2-negative breast cancer. The study is an open-label, uncontrolled Phase III trial designed to address the challenges of treating this condition, which currently has a median survival of only 3 to 6 months despite existing treatments. Participants receive Sacituzumab Govitecan intravenously at a dose of 10 mgkg on Days 1 and 8 of each 21-day treatment cycle until the disease worsens or side effects become unacceptable. Intrathecal pemetrexed chemotherapy is given via intracerebroventricular or lumbar puncture starting on Day 2, delivered in three phases induction therapy 15 mg twice weekly for 2 weeks, consolidation therapy once weekly for 4 weeks, and maintenance therapy once monthly for patients who respond well, continuing until relapse or death. Phase I involved 3 to 6 patients to assess dose tolerance, with possible dose adjustments based on side effects before moving to Phase II. During the study, participants undergo regular monitoring for side effects and treatment response, including assessment of the maximal tolerated dose and clinical response rate over the treatment period and up to two months after. Safety is closely observed through treatment-related adverse event tracking. The studys total duration includes initial treatment cycles and follow-up to evaluate ongoing effects and tolerability. This comprehensive approach helps researchers understand the treatments potential and safety profiles in this patient group.
CONDITIONS
Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
Z
Zhenyu Pan
G
Guozi Yang
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Guangzhou Medical University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Repeated 21-day cycles until disease progression or unacceptable toxicity
Participants receive intravenous Sacituzumab Govitecan on Days 1 and 8 of each 21-day cycle combined with intrathecal pemetrexed chemotherapy administered in three phases: induction therapy (15 mg twice weekly for 2 weeks), consolidation therapy (once weekly for 4 weeks), and maintenance therapy (once monthly for those responding). Treatment continues until disease progression or unacceptable toxicity.
Multiple visits aligned with drug administration schedule including twice weekly visits during induction, weekly visits during consolidation, and monthly visits during maintenance
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Zhenyu Pan, Guozi Yang, Hua He...
https://pubmed.ncbi.nlm.nih.gov/32733606/Aditya Bardia, Sara A Hurvitz, Sara M Tolaney...
https://pubmed.ncbi.nlm.nih.gov/33882206/Zhenyu Pan, Guozi Yang, Jiuwei Cui...
https://pubmed.ncbi.nlm.nih.gov/31544065/Hope S Rugo, Aditya Bardia, Frederik Marmé...
https://pubmed.ncbi.nlm.nih.gov/37633306/Guangzhou Medical University
Lead Sponsor